Households, and not schools, are the major route of coronavirus disease 2019 (COVID-19) transmission for those ≤18 years of age, according to across-sectional study of nearly 400 Hong Kong children and youths who contracted COVID-19 in 2020.
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 inﬂuenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.
A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.
Administering two doses of NVX-CoV2373 (Novavax) vaccine lowers the occurrence of virologically confirmed symptomatic mild, moderate, or severe COVID-19 in healthy adults, according to data from the 2019nCoV-302* study.
The odds of severe COVID-19 illness, hospitalization, and long COVID-19 were significantly reduced by more than half after two doses of vaccines compared with those unvaccinated, reveal data from a real-world study. Even if fully vaccinated people were infected, they were twice as likely to be completely asymptomatic than unvaccinated ones.
The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.
A manikin study has shown that use of the standard face shield is not enough to protect against droplet dispersion during oropharyngeal COVID-19 swabs, but the SG Shield results in significant reduction of droplet contamination to the swab provider’s face and chest.
Cardiac manifestations, such as acute myocardial infarction (AMI) and myocarditis, after vaccination for the coronavirus disease 2019 (COVID-19) are more common in men, according to a recent Singapore study. AMI is more likely to arise after the first shot, while myocarditis becomes more common after the second dose.